Lab-Grown stem cells could speed recovery after transplant for blood cancers
NCT ID NCT02730299
First seen Feb 28, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This Phase 3 trial tested a new stem cell product called NiCord (omidubicel) for people with blood cancers like leukemia and lymphoma. NiCord is made by growing stem cells from donated umbilical cord blood in a lab, so patients get more cells. The study compared NiCord to standard cord blood transplants in 125 patients. The goal was to see if NiCord helps the immune system recover faster and lowers the risk of serious infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Careggi University Hospital
Florence, 50134, Italy
-
Chaim Sheba Medical Center, The Edmond and Lily Safra Children's hospital
Tel Litwinsky, Israel
-
Children's Hospital Colorado
Denver, Colorado, 80045, United States
-
Children's Medical Center of Dallas
Dallas, Texas, 75235, United States
-
City of Hope
Los Angeles, California, 91010, United States
-
Cleveland Clinic Children's
Cleveland, Ohio, 44195, United States
-
Dana-Dwek Children's Hospital, Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Hadassah Medical Center
Jerusalem, Israel
-
Henry Ford Medical Center
Detroit, Michigan, United States
-
Hospital Israelita Albert Einstein
São Paulo, Brazil
-
Hospital Universitari Vall d'Hebron pediatrics
Barcelona, 08035, Spain
-
Hospital Universitario La Fe
Valencia, 46009, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Spain
-
Hospital Universitario y Politécnico La Fe (pediatric)
Valencia, Spain
-
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, São Paulo, 05403-010, Brazil
-
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Pediatrics
São Paulo, São Paulo, 05403-010, Brazil
-
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
São Paulo, São Paulo, 14048-900, Brazil
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
-
ICO Bellvitge
Barcelona, 08908, Spain
-
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA
Rio de Janeiro, Rio de Janeiro, 20230-130, Brazil
-
Instituto Português de Oncologia de Lisboa Francisco Gentil
Lisbon, 1099-023, Portugal
-
Loyola University, Cardinal Bernardin Cancer Center
Maywood, Illinois, 60153, United States
-
Manchester University NHS Foundation Trust
Manchester, M13 9WL, United Kingdom
-
National University Cancer Institute
Singapore, 119074, Singapore
-
Northwestern University
Evanston, Illinois, 60208, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Ospedale Pediatrico Bambino Gesù
Rome, 00165, Italy
-
Prinses Maxima Centrum voor Kinderoncologie B.V.
Utrecht, 3584 CS, Netherlands
-
Queen Elizabeth Hospital
Birmingham, B15 2GW, United Kingdom
-
Rabin Medical Center, Beilinson Hospital
Petah Tikva, Israel
-
Rambam
Haifa, Israel
-
Robert Debré
Paris, 75019, France
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Sant Joan de Deu
Barcelona, 08950, Spain
-
Singapore General Hospital
Singapore, 169608, Singapore
-
St James Hospital
Leeds, LS9 7TF, United Kingdom
-
Stanford University Cancer Institute
Palo Alto, California, United States
-
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
-
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
-
The University of Maryland Medicine Center
Baltimore, Maryland, 21201, United States
-
UC San Diego Moores Cancer Center
San Diego, California, 92093, United States
-
UCLA
Los Angeles, California, 90095, United States
-
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224, United States
-
University Hospital Vall d'Hebron
Barcelona, 08035, Spain
-
University Medical Center Utrecht
Utrecht, 3503 AB, Netherlands
-
University of Kansas Cancer Center
Westwood, Kansas, 66205, United States
-
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22903, United States
-
West Cancer Clinic
Germantown, Tennessee, 38138, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NiCord (omidubicel) – lab-grown stem cells from umbilical cord blood
What this could lead to
If it works, this could offer a faster, safer way to rebuild the immune system after a stem cell transplant for blood cancers, reducing infections and hospital stays.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. Risks include graft failure, infection, and side effects from the transplant process itself.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.